Document 0045
 DOCN  M9490045
 TI    Recommendations of the U.S. Public Health Service Task Force on the use
       of zidovudine to reduce perinatal transmission of human immunodeficiency
       virus.
 DT    9411
 SO    MMWR Morb Mortal Wkly Rep. 1994 Aug 5;43(RR-11):1-20. Unique Identifier
       : AIDSLINE MED/94322749
 AB    These recommendations update the interim guidelines (1) developed by the
       U.S. Public Health Service for the use of zidovudine (ZDV) to reduce the
       risk for perinatal transmission of human immunodeficiency virus (HIV)
       infection. The recently reported results of AIDS Clinical Trials Group
       Protocol 076 demonstrated that ZDV administered to a selected group of
       HIV-infected pregnant women and their infants can reduce the risk for
       perinatal HIV transmission by approximately two-thirds. The regimen used
       in this trial included antenatal oral administration of ZDV beginning at
       14-34 weeks of gestation and continuing throughout pregnancy, followed
       by intrapartum intravenous ZDV and postnatal oral administration of ZDV
       to the infant for 6 weeks after delivery. This document summarizes the
       results of the trial, discusses limitations in the interpretation of the
       results, reviews the potential long-term adverse effects of this ZDV
       regimen for infants and women, and provides recommendations for the use
       of ZDV to reduce perinatal transmission and for medical monitoring of
       pregnant women and infants receiving this therapy. Because the clinical
       status of many HIV-infected women may differ from that of the women in
       this trial, the recommendations should be tailored to each woman's
       clinical situation. The potential benefits, unknown long-term effects,
       and gaps in knowledge about her specific clinical situation must be
       discussed with the woman. This information is intended to provide a
       basis for discussion between the woman and her healthcare provider so
       that the woman can weigh the risks and benefits of such therapy and make
       informed decisions about her treatment.
 DE    Adult  Drug Administration Schedule  Female  Fetal Monitoring
       Gestational Age  Hematologic Tests  Human  HIV
       Infections/CONGENITAL/DRUG THERAPY/*PREVENTION & CONTROL/  TRANSMISSION
       Infant  Infant, Newborn  Leukocyte Count  Pregnancy  Pregnancy
       Complications, Infectious/*DRUG THERAPY  *Prenatal Exposure Delayed
       Effects  Randomized Controlled Trials  T4 Lymphocytes
       Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       GUIDELINE  JOURNAL ARTICLE  PRACTICE GUIDELINE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).